Medincell SA Total Liabilities

Latest as of March 2026: €104.99 Million EUR ≈ $122.74 Million USD

Medincell SA total liabilities. Based on the latest financial reports, Medincell SA (MEDCL) has total liabilities worth €104.99 Million EUR (≈ $122.74 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check MEDCL asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Medincell SA (2016–2026)

Total liabilities of Medincell SA from 2016 to 2026. This chart illustrates how Medincell SA's total liabilities have evolved over time, based on quarterly financial data. Explore how much of Medincell SA's assets are long-term investments to see how much of total assets are deployed in long-term investments.

Medincell SA Competitors by Total Liabilities

The table below lists competitors of Medincell SA ranked by their total liabilities.

Company Country Total Liabilities
Elco Ltd
TA:ELCO
Israel ILA22.59 Billion
Raymond Limited
NSE:RAYMOND
India Rs16.20 Billion
Kornit Digital Ltd
NASDAQ:KRNT
USA $64.70 Million
Vesuvius India Limited
NSE:VESUVIUS
India Rs4.86 Billion
Tourism Finance Corporation of India Limited
NSE:TFCILTD
India Rs10.57 Billion
Apogee Enterprises Inc
NASDAQ:APOG
USA $589.44 Million
Heartland Express Inc
NASDAQ:HTLD
USA $418.51 Million
Asseco Business Solutions S.A.
WAR:ABS
Poland zł138.21 Million

Liability Composition Analysis (2016–2026)

This chart breaks down Medincell SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Medincell SA (MEDCL) total assets.

Liquidity & Leverage Metrics

Medincell SA Total Liabilities Ratios Explained

Medincell SA total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 4.67 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 34.27 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.97 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Medincell SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Medincell SA (2016–2026)

The table below shows the annual total liabilities of Medincell SA from 2016 to 2026.

Year Total Liabilities Change
2026-03-31 €104.99 Million
≈ $122.74 Million
-1.71%
2025-03-31 €106.82 Million
≈ $124.88 Million
+37.35%
2024-03-31 €77.77 Million
≈ $90.92 Million
+8.57%
2023-03-31 €71.63 Million
≈ $83.75 Million
+24.20%
2022-03-31 €57.67 Million
≈ $67.43 Million
+5.46%
2021-03-31 €54.69 Million
≈ $63.94 Million
+26.41%
2020-03-31 €43.27 Million
≈ $50.58 Million
+36.31%
2019-03-31 €31.74 Million
≈ $37.11 Million
-14.45%
2018-03-31 €37.10 Million
≈ $43.38 Million
+45.20%
2017-03-31 €25.55 Million
≈ $29.87 Million
+159.47%
2016-03-31 €9.85 Million
≈ $11.51 Million
--

About Medincell SA

PA:MEDCL France Biotechnology
Market Cap
$1.11 Billion
€946.58 Million EUR
Market Cap Rank
#9567 Global
#152 in France
Share Price
€26.36
Change (1 day)
+0.38%
52-Week Range
€20.24 - €37.62
All Time High
€38.46
About

MedinCell S.A. engages in the research and development of biodegradable polymer-based processes for the controlled and prolonged delivery of active pharmaceutical ingredients into the human body and animals in France. The company offers UZEDY, a subcutaneous risperidone for the treatment of schizophrenia. It also develops mdc-TJK, a subcutaneous injection, which is in NDA stage for the treatment … Read more